V

    Vera Therapeutics Inc (VERA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $34.08
    -0.11 (-0.32%)

    Market Cap: $2.46B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    32%(7/22)
    Avg Surprise
    -34.46%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.68
    Range$-1.83 - $-1.39
    5 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-1.60+4.7%
    60d ago$-1.64+2.6%
    30d ago$-1.54+8.2%
    7d ago$-1.54+8.2%
    Current$-1.68
    Revenue Consensus
    $6M
    Range$0 - $15M
    9 analysts
    Dec 31, 2026
    EPS Consensus$-1.68
    Range$-2.46 - $-1.12
    8 analysts
    Revenue Consensus
    $19M
    Range$6M - $45M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.68---
    Sep 26EST
    		-$-1.68---
    Jun 26
    		$-1.52$-1.60+5.00%Beat-26.7%
    Mar 26
    		$-1.69$-1.37-23.36%Miss-108.6%
    Dec 25
    		$-1.39$-1.34-3.73%Miss-93.1%
    Sep 25
    		$-1.26$-1.20-5.00%Miss-48.2%
    Jun 25
    		$-1.20$-0.62-93.55%Miss-93.5%
    Mar 25
    		$-0.81$-0.78-3.85%Miss-44.6%
    Dec 24
    		$-0.72$-0.81+11.11%Beat-24.1%
    Sep 24
    		$-0.85$-0.62-37.10%Miss-88.9%
    Jun 24
    		$-0.62$-0.54-14.81%Miss-34.8%
    Mar 24
    		$-0.56$-0.53-5.66%Miss+30.0%
    Dec 23
    		$-0.58$-0.51-13.73%Miss+50.8%
    Sep 23
    		$-0.45$-0.54+16.67%Beat+50.5%
    Jun 23
    		$-0.46$-0.74+37.84%Beat+16.4%
    Mar 23
    		$-0.80$-0.45-77.78%Miss-12.7%
    Dec 22
    		$-1.18$-0.90-31.11%Miss-49.4%
    Sep 22
    		$-0.91$-0.90-1.11%Miss-152.8%
    Jun 22
    		$-0.55$-0.78+29.49%Beat-66.7%
    Mar 22
    		$-0.71$-0.64-10.94%Miss+94.2%
    Dec 21
    		$-0.79$-0.46-71.74%Miss+60.8%
    Sep 21
    		$-0.36$-0.59+38.98%Beat-71.8%
    Jun 21
    		$-0.33$-0.45+26.67%Beat-94.8%
    Mar 21
    		$-12.23$-1.94-530.41%Miss-10415.9%
    Dec 20
    		$-2.02N/AN/ABeat-
    Sep 20
    		$-0.21N/AN/ABeat-
    Jun 20
    		$-0.17N/AN/ABeat-
    Mar 20
    		$-0.12N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-5.82EV/EBITDA-3.60x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-91.70%ROIC-68.26%
    Financial Health
    Debt/Equity0.18xInterest Coverage-55.38x
    Current Ratio10.92xQuick Ratio10.92x
    Trading Statistics
    Beta0.95Avg Volume2.18M
    52-Week High$56.0552-Week Low$21.64

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$33.68
    SMA 20$32.30
    SMA 50$36.20
    SMA 200$39.32
    EMA 10$33.80
    EMA 20$33.54
    EMA 50$34.68
    EMA 200$35.99

    MACD

    Line: -0.07Signal: -0.65Hist: 0.57

    ADX

    ADX: 22.5+DI: 24.0-DI: 20.8

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down52.0
    PSAR$32.12

    Bollinger Bands

    Upper Band$36.32
    Lower Band$28.28
    %B Position2487%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    51.2

    Momentum Oscillators

    Stoch %K67.0
    Stoch %D77.9
    Williams %R-35.6
    ROC (10d)7.7%
    Momentum2.45
    CCI (20d)72.5
    MFI (14d)66.3

    Volatility Measures

    ATR (14d)$1.92(5.6%)
    StdDev (20d)2.01
    Hist Vol67.8%(High)

    Volume Flow

    VWAP$33.88
    OBV10.0M
    AD Line15.9M
    CMF (20d)-0.016

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.7x
    VWMA (20d)$32.19

    Pivot Points

    R3$35.79
    R2$35.13
    R1$34.66
    Pivot Point$34.00
    S1$33.53
    S2$32.87
    S3$32.40

    Advanced Oscillators

    TSI-1.44
    Ultimate Osc58.0
    KST-68.48

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$-1,127,000$0$0$0N/A$0$0$0$-635,000$0
    Gross Profit$0$0$1.13M$0$0$0N/A$0$0$0$635,000$0
    Operating Expenses$112.49M$125.13M$94.21M$83.93M$80.14M$57.19M$48.91M$49.80M$37.34M$31.11M$27.03M$21.76M
    R&D$60.08M$86.01M$59.31M$56.47M$58.20M$41.28M$33.35M$40.31M$29.31M$23.20M$20.79M$16.10M
    SG&A$52.41M$39.12M$34.90M$27.46M$21.95M$15.92M$15.57M$9.49M$8.03M$7.91M$6.24M$5.66M
    Operating Income$-112,490,000$-125,132,000$-94,206,000$-83,932,000$-80,141,000$-57,194,000$-48,914,000$-49,801,000$-37,343,000$-31,112,000$-27,028,000$-21,756,000
    Interest Income$5.35M$6.36M$5.52M$5.74M$6.32M$6.91M$6.66M$4.76M$5.10M$4.19M$1.96M$2.16M
    Interest Expense$1.85M$1.82M$1.91M$1.96M$1.87M$1.79M$1.87M$1.94M$1.91M$1.91M$1.05M$943,000
    Income Before Tax$-109,473,000$-121,032,000$-91,096,000$-80,293,000$-76,531,000$-51,694,000$-43,424,000$-46,632,000$-33,708,000$-28,383,000$-25,654,000$-20,104,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-109,473,000$-121,032,000$-91,097,000$-80,293,000$-76,531,000$-51,694,000$-43,425,000$-46,632,000$-33,708,000$-28,383,000$-25,655,000$-20,104,000
    EBITDA$-113,293,000$-125,628,000$-95,045,000$-84,548,000$-82,592,000$-59,033,000$-50,009,000$-51,657,000$-39,494,000$-32,132,000$-27,725,000$-24,402,000
    EBIT$-112,973,000$-125,564,000$-94,708,000$-84,069,000$-80,977,000$-56,808,000$-48,215,000$-49,457,000$-36,900,000$-30,663,000$-26,558,000$-21,319,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VERA

    News

    What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders

    Vera Therapeutics (VERA) reported a significant widening of net losses in Q2 2026 and the first half of 2026, reaching US$109.47 million and US$230.51 million respectively, leading to increased cash burn and pressure on per-share results. This performance highlights the high costs associated with developing its drug TRUTAKNA and the broader atacicept program, raising concerns about funding risk and potential dilution. Despite the financial challenges, the company's investment narrative hinges on the eventual commercial viability of TRUTAKNA and successful navigation of regulatory hurdles.

    Sahm•8/19/26•
    Bearish

    Kynam Capital (VERA) now holds 4.01% beneficial stake in Vera Therapeutics

    Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang have reported a 4.01% beneficial ownership stake in Vera Therapeutics, Inc. Class A common stock. This represents 2,890,059 shares with shared voting and dispositive power. The filing indicates that their ownership is 5 percent or less of the class.

    Stock Titan•8/14/26•
    Neutral

    Is Vera Therapeutics (VERA) Undervalued On FDA Approval For TRUTAKNA?

    Vera Therapeutics (VERA) received accelerated FDA approval for TRUTAKNA for IgA nephropathy, but its share price has fallen recently despite strong long-term returns. The company is currently loss-making and trades at a P/B ratio of 5.4x, which is below peers but above the broader biotech industry. A Simply Wall St DCF model suggests the stock is significantly undervalued compared to its estimated future cash flow value.

    Sahm•8/14/26•
    Neutral

    Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise

    Vera Therapeutics' President and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares on June 23, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, with the shares sold at a weighted-average price of $37.9311 for 18,412 shares and $38.43 for the remaining 88 shares. This transaction was disclosed in an amended Form 4 filing correcting previous beneficial ownership amounts.

    Stock Titan•8/13/26•
    Neutral

    Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan

    Vera Therapeutics (VERA) CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares in open-market transactions on May 12, 2026. The sales, totaling approximately $680K in gross proceeds, were executed under a pre-approved Rule 10b5-1 trading plan adopted on January 9, 2026. After these transactions, Fordyce beneficially owns 590,551 stock options and 235,244 shares of Class A Common Stock directly.

    Stock Titan•8/13/26•
    Neutral

    Frequently Asked Questions About VERA

    Does VERA pay dividends?
    Vera Therapeutics Inc (VERA) does not currently pay a regular dividend.
    What is VERA's market cap?
    Vera Therapeutics Inc (VERA) has a market capitalization of $2.46B with a current stock price of $34.08.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In